Exemption Number Allows Triarco’s Aminogen Enzyme Ingredient to Be Sold in Canada
Triarco says that unpublished preclinical studies and published studies have been done to determine Aminogen’s safety and toxicity guidelines. Moreover, it says, earlier this year Health Canada’s Natural Health Products Directorate cited a clinical study done on Aminogen as being “one of only two studies available to support fungal proteolytic enzyme dosing guidelines.”
24 Sep 2012 --- Triarco Industries (Wayne, NJ) announced that its patented Aminogen enzyme ingredient has been granted an exemption number by Health Canada. This number allows the product to be legally sold in Canada while its submitted license application awaits review by Health Canada.
Under Canada’s Natural Health Products Regulation, dietary supplements must have a product license number or an exemption number in order to be sold in Canada. Products are granted exemption numbers only after they have undergone an initial assessment and have been determined to meet safety, quality, and efficacy criteria.
Triarco says that unpublished preclinical studies and published studies have been done to determine Aminogen’s safety and toxicity guidelines. Moreover, it says, earlier this year Health Canada’s Natural Health Products Directorate cited a clinical study done on Aminogen as being “one of only two studies available to support fungal proteolytic enzyme dosing guidelines.”
“This [exemption number from Health Canda] also reflects well on Aminogen in other international markets,” says Triarco president Rodger Rohde Jr. “People are paying attention to which products are approved for sale under the new Canadian regulations.”
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
